1World Health Organisation. Depression and Other Common Mental Disorders Global Health Estimates. WHO, 2017.
2Rush, AJ, Trivedi, MH, Wisniewski, SR, Nierenberg, AA, Stewart, JW, Warden, D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163: 1905–17.
3Carvalho, AF, Berk, M, Hyphantis, TN, McIntyre, RS. The integrative management of treatment-resistant depression: a comprehensive review and perspectives. Psychother Psychosom 2014; 83: 70–88.
4Rosenblat, JD, McIntyre, RS, Alves, GS, Fountoulakis, KN, Carvalho, AF. Beyond monoamines-novel targets for treatment-resistant depression: a comprehensive review. Curr Neuropharmacol 2015; 13: 636–55.
5Ludka, FK, Constantino, LC, Kuminek, G, Binder, LB, Zomkowski, AD, Cunha, MP, et al. Atorvastatin evokes a serotonergic system-dependent antidepressant-like effect in mice. Pharmacol Biochem Behav 2014; 122: 253–60.
6Köhler, O, Gasse, C, Petersen, L, Ingstrup, KG, Nierenberg, AA, Mors, O, et al. The effect of concomitant treatment with SSRIs and statins: a population-based study. Am J Psychiatry 2016; 173: 807–15.
7Parsaik, AK, Singh, B, Murad, MH, Singh, K, Mascarenhas, SS, Williams, MD, et al. Statins use and risk of depression: a systematic review and meta-analysis. J Affect Disord 2014; 160: 62–7.
8Salagre, E, Fernandes, BS, Dodd, S, Brownstein, DJ, Berk, M. Statins for the treatment of depression: a metaanalysis of randomized, double-blind, placebo-controlled trials. J Affect Disord 2016; 200: 235–42.
9Köhler-Forsberg, O, Gasse, C, Berk, M, Østergaard, SD. Do statins have antidepressant effects? CNS Drugs 2017; 31: 335–43.
10McFarland, AJ, Anoopkumar-Dukie, S, Arora, DS, Grant, GD, McDermott, CM, Perkins, AV, et al. Molecular mechanisms underlying the effects of statins in the central nervous system. Int J Mol Sci 2014; 15: 20607–37.
11Herbet, M, Izdebska, M, Piątkowska-Chmiel, I, Poleszak, E, Jagiełło-Wójtowicz, E. Estimation of oxidative stress parameters in rats after simultaneous administration of rosuvastatin with antidepressants. Pharmacol Rep 2016; 68: 172–6.
12Moylan, S, Berk, M, Dean, OM, Samuni, Y, Williams, LJ, O'Neil, A, et al. Oxidative & nitrosative stress in depression: why so much stress? Neurosci Biobehav Rev 2014; 45: 46–62.
13Köhler, CA, Freitas, TH, Maes, M, de Andrade, NQ, Liu, CS, Fernandes, BS, et al. Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatr Scand 2017; 135: 373–87.
14Köhler, CA, Freitas, TH, Stubbs, B, Maes, M, Solmi, M, Veronese, N, et al. Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and meta-analysis. Mol Neurobiol 2018; 55: 4195–206.
15Parekh, A, Smeeth, D, Milner, Y, Thuret, S. The role of lipid biomarkers in major depression. Healthcare 2017; 5: 5.
16Lamers, F, Milaneschi, Y, de Jonge, P, Giltay, EJ, Penninx, BWJH. Metabolic and inflammatory markers: associations with individual depressive symptoms. Psychol Med 2018; 48: 1102–10.
17Stewart, JW, McGrath, PJ, Fava, M, Wisniewski, SR, Zisook, S, Cook, I, et al. Do atypical features affect outcome in depressed outpatients treated with citalopram? Int J Neuropsychopharmacol 2010; 13: 15–30.
18Johnson-Anuna, LN, Eckert, GP, Keller, JH, Igbavboa, U, Franke, C, Fechner, T, et al. Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex. J Pharmacol Exp Ther 2005; 312: 786–93.
19Thelen, KM, Rentsch, KM, Gutteck, U, Heverin, M, Olin, M, Andersson, U, et al. Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin. J Pharmacol Exp Ther 2006; 316: 1146–52.
20Ma, K, Zhang, H, Baloch, Z. Pathogenetic and therapeutic applications of tumor necrosis factor-α (TNF-α) in major depressive disorder: a systematic review. Int J Mol Sci 2016; 17: 733–53.
21Liu, Y, Ho, RC, Mak, A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and metaregression. J Affect Disord 2012; 139: 230–9.
22First, MB, Williams, JBW, Karg, RS, Spitzer, RL. Structured Clinical Interview for DSM-5—Research Version (SCID-5 for DSM-5, Research Version; SCID-5-RV). American Psychiatric Association, 2015.
23Gougol, A, Zareh-Mohammadi, N, Raheb, S, Farokhnia, M, Salimi, S, Iranpour, N, et al. Simvastatin as an adjuvant therapy to fluoxetine in patients with moderate to severe major depression: a double-blind placebo-controlled trial. J Psychopharmacol 2015; 29: 575–81.
24Montgomery, SA, Asberg, A. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–9.
25Jakobsen, JC, Katakam, KK, Schou, A, Hellmuth, SG, Stallknecht, SE, Leth-Møller, K, et al. Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and trial sequential analysis. BMC Psychiatry 2017; 17: 58.
26Husain, MI, Chaudhry, IB, Husain, N, Khoso, AB, Rahman, RR, Hamirani, MM, et al. Minocycline as an adjunct for treatment-resistant depressive symptoms: a pilot randomised placebo-controlled trial. J Psychopharmacol 2017; 31: 1166–75.
27Hamilton, M. Rating depressive patients. J Clin Psychiatry 1980; 41: 21–4.
28Joint Formulary Committee. British National Formulary. BMJ Group and Pharmaceutical Press, 2017.
29Taylor, D, Barnes, TRE, Young, AH. The Maudsley Prescribing Guidelines (13th edn). CRC Press, 2018.
30Carmody, T, Rush, AJ, Bernstein, I, et al. The Montgomery Äsberg and the Hamilton ratings of depression: a comparison of measures. Eur Neuropsychopharmacol 2006; 16: 601–11.
31Carmody, TJ, Rush, AJ, Bernstein, I, Warden, D, Brannan, S, Burnham, D, et al. The Montgomery Asberg and the Hamilton ratings of depression: a comparison of measures. Eur Neuropsychopharmacol 2006; 16: 601–11.
32Busner, J, Targum, SD. The Clinical Global Impressions scale. Psychiatry (Edgmont) 2007; 4: 28–37.
33Spitzer, RL, Kroenke, K, Williams, JB, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006; 166: 1092–7.
34Morisky, DE, Green, LW, Levine, DM. Concurrent and predictive validity of a self-reported measure of medication adherence and long-term predictive validity of blood pressure control. Med Care 1986; 24: 67–74.
35Lingjaerde, O, Ahlfors, UG, Bech, P, Dencker, SJ, Elgen, K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987; 334: 1–100.
36Fleiss, JL. Measuring nominal scale agreement among many raters. Psychol Bull 1971; 76: 378–82.
37Muthén, LK, Muthén, BO. Mplus User's Guide (7th edn). Muthén & Muthén, 1998–2012.
38Fritz, MS, MacKinnon, DP. Required sample size to detect the mediated effect. Psychol Sci 2007; 18: 233–9.
39Wium-Andersen, MK, Orsted, DD, Nielsen, SF, et al. Elevated C-reactive protein levels, psychological distress, and depression in 73, 131 individuals. JAMA Psychiatry 2013; 70: 176–84.
40Benati, D, Ferro, M, Savino, MT, Ulivieri, C, Schiavo, E, Nuccitelli, A, et al. Opposite effects of simvastatin on the bactericidal and inflammatory response of macrophages to opsonized S. aureus. J Leukoc Biol 2009; 87: 433–42.
41Loike, JD. Statin inhibition of Fc receptor-mediated phagocytosis by macrophages is modulated by cell activation and cholesterol. Arterioscler Thromb Vasc Biol 2004; 24: 2051–6.
42Muniz-Junqueira, MI, Karnib, SR, de Paula-Coelho, VN, Junqueira, LF. Effects of pravastatin on the in vitro phagocytic function and hydrogen peroxide production by monocytes of healthy individuals. Int Immunopharmacol 2006; 6: 53–60.
43Salman, H, Bergman, M, Djaldetti, M, Bessler, H. Hydrophobic but not hydrophilic statins enhance phagocytosis and decrease apoptosis of human peripheral blood cells in vitro. Biomed Pharmacother 2008; 62: 41–5.
44Tanaka, N, Abe-Dohmae, S, Iwamoto, N, Fitzgerald, ML, Yokoyama, S. HMG-CoA reductase inhibitors enhance phagocytosis by upregulating ATP-binding cassette transporter A7. Atherosclerosis 2011; 217: 407–14.
45Djaldetti, M, Salman, H, Bergman, M, Bessler, H. Effect of pravastatin, simvastatin and atorvastatin on the phagocytic activity of mouse peritoneal macrophages. Exp Mol Pathol 2006; 80: 160–4.
46Sierra, S, Ramos, MC, Molina, P, Esteo, C, Vázquez, JA, Burgos, JS. Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. J Alzheimers Dis 2011; 23: 307–18.
47Setiawan, E, Attwells, S, Wilson, AA, Mizrahi, R, Rusjan, PM, Miler, L, et al. Association of translocator protein total distribution volume with duration of untreated major depressive disorder: a cross-sectional study. Lancet Psychiatry 2018; 5: 339–47.